This clinical trial is focused on studying a condition known as Burning Mouth Syndrome (BMS). BMS is a condition characterized by a burning sensation in the mouth without an obvious cause. The treatment being investigated in this study is a medication called Clonazepam, which is typically used to treat seizures and panic disorders. In this trial, Clonazepam will be applied topically, meaning it will be used directly on the affected area in the mouth, rather than being taken as a pill.

The purpose of the study is to explore the effects of this topical treatment on pain intensity, sensory changes, and jaw function in individuals with BMS. The study will be conducted in two parts. The first part will last for two weeks, during which participants will use the topical Clonazepam treatment. Researchers will assess how the treatment affects pain and other symptoms, as well as gather feedback on the participants’ experiences with the treatment. The second part involves a long-term follow-up over six months, where participants will continue with either Clonazepam or a control treatment, chosen without knowing which one they are receiving. This follow-up will help understand the long-term effects of the treatment.

Throughout the study, various aspects will be monitored, including changes in pain levels, any sensory changes such as taste, and how the condition affects daily activities. The study aims to provide insights into how effective topical Clonazepam is in managing the symptoms of Burning Mouth Syndrome and to understand the participants’ overall impression of the treatment.